Inclusion Criteria:  Completion of a Cytokinetics trial investigating CK-3773274 LVEF ≥55% at the Screening Visit  Exclusion Criteria:  Has taken any investigational study drug other than CK-3773274 within 30 days prior to screening  Since completion of a previous trial of CK-3773274 has:  Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) <30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate (HR) <100 bpm and/or rhythm is stable >30 days Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation) since the completion of a prior trial of CK-3773274. Has current obstructive coronary artery disease (>70% stenosis documented in one or more arteries) Has moderate or severe aortic valve stenosis Had a confirmed LVEF <40% with an associated dose interruption during CY 6021 History of syncope or sustained ventricular tachyarrhythmia with exercise within 30 days prior to screening History of appropriate ICD shock within 30 days prior to screening Has received treatment with mavacamten